Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scribe Therapeutics
Biotech
Scribe records upsized $129M IPO to fund genetic med trials
In vivo gene editing outfit Scribe has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week
Darren Incorvaia
Jul 24, 2026 4:00am
Scribe aims for $96M IPO to fund lipid-lowering genetic meds
Jul 20, 2026 9:48am
Scribe notes IPO plan to push lipid-lowering meds through clinic
Jul 6, 2026 7:54am
Scribe eyes clinic as CRISPR candidates lower lipids in animals
Nov 17, 2025 9:22am
Gene editor Scribe slims down workforce as it readies for clinic
Jan 8, 2025 5:33pm
Sanofi, Scribe seal new in vivo collab worth more than $1.2B
Jul 17, 2023 11:30am
